非选择性β受体阻滞剂与肝硬化患者门静脉血栓风险:一项前瞻性纵向研究结果
该前瞻性纵向研究纳入108例无门静脉血栓的肝硬化门诊患者(78%为Child A级),每3或6个月行多普勒超声检查,中位随访19个月。11例发生门静脉血栓。基线非选择性β受体阻滞剂使用(HR 10.56;95%CI 1.35-82.73;P=0.025)及中或大型食管静脉曲张(HR 5.67;95%CI 1.49-21.63;P=0.011)与门静脉血栓发生相关。非选择性β受体阻滞剂虽显著降低心率和门静脉血流速度,但二者与门静脉血栓发生无关。
要点
- 基线使用非选择性β受体阻滞剂与门静脉血栓发生相关(HR 10.56;95%CI 1.35-82.73;P=0.025)。
- 基线中或大型食管静脉曲张与门静脉血栓发生相关(HR 5.67;95%CI 1.49-21.63;P=0.011)。
- 非选择性β受体阻滞剂降低心率和门静脉血流速度,但二者与门静脉血栓发生无关。
核心结论
- 本研究发现门静脉血栓发生与基线食管静脉曲张相关,但提示该关联可能由非选择性β受体阻滞剂暴露解释,且独立于对心率和门静脉血流速度的影响。
- 非选择性β受体阻滞剂患者中门静脉血栓发生的机制尚需阐明,以优化肝硬化患者非选择性β受体阻滞剂治疗的目标人群。
研究设计与样本
- 前瞻性纵向研究,2014年1月至2017年2月纳入108例无门静脉血栓的肝硬化门诊患者,78%为Child A级。
- 每3或6个月行多普勒超声检查,中位随访19个月。
主要发现
- 11例患者发生门静脉血栓。
- 基线非选择性β受体阻滞剂使用与门静脉血栓发生相关(HR 10.56;95%CI 1.35-82.73;P=0.025)。
- 基线中或大型食管静脉曲张与门静脉血栓发生相关(HR 5.67;95%CI 1.49-21.63;P=0.011)。
- 非选择性β受体阻滞剂显著降低基线心率(P<0.001)和门静脉血流速度(P=0.005),但二者与门静脉血栓发生无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nonmalignant portal vein thrombosis is a significant event in the course of cirrhosis that can contraindicate liver transplantation and even impact survival after the surgical procedure. Risk factors are not completely known or validated and are still debated. AIM: To identify in patients with cirrhosis the risk factors for portal vein thrombosis that are assessable in clinical practice. METHODS: Between January 2014 and February 2017, 108 outpatients with cirrhosis and no portal vein thrombosis (78% Child A) were enrolled. Doppler ultrasound was performed every 3 or 6 months, for a median follow up of 19 months. RESULTS: Portal vein thrombosis developed in 11 patients. Nonselective beta-blockade (hazard ratio [HR] 10.56; 95% confidence interval [CI]: 1.35-82.73; P = 0.025), and medium or large-sized oesophageal varices (HR 5.67; 95% CI: 1.49-21.63; P = 0.011) at baseline were associated with portal vein thrombosis development. Although heart rate (P < 0.001) and portal blood flow velocity at baseline (P = 0.005) were significantly reduced by nonselective beta-blockers, they were not related to portal vein thrombosis development. CONCLUSIONS: Our findings confirm an association between portal vein thrombosis development and oesophageal varices at baseline, but suggest that the association could be explained by exposure to nonselective beta-blockers, independently from effects on heart rate and portal blood flow velocity. The mechanisms that explain portal vein thrombosis development in patients on nonselective beta-blockers require elucidation in order to optimise targeting of nonselective beta-blockade in patients with cirrhosis.
引用
- Nery F, Correia S, Macedo C, et al. Nonselective beta-blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study. Aliment Pharmacol Ther. 2019. PMID: 30671978. doi:10.1111/apt.15137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。